

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Eva Turley	)	Group Art Unit: unknown
	)	
Serial No. Unknown	)	
(Divisional of 09/210,896)	)	Examiner: unknown
	)	
Filed: concurrently herewith	)	
	)	
For: Enhanced Affinity Hyaluronan	)	
Binding Peptides	)	

The Commissioner of Patents  
& Trademarks  
Washington, D.C. 20231  
U.S.A.

Dear Sir:

**PRELIMINARY AMENDMENT**

We are simultaneously filing herewith a divisional application of United States serial no. 09/210,896 filed on December 16, 1998. Please enter the following amendment in the divisional application.

**In the Specification:**

Please amend page 1, lines 3 to 5 as follows:


This application is a divisional of U.S. Patent Application Serial no. 09/210,896 filed on December 16, 1998 which claims the benefit under 35 USC§119(e) of United States provisional application serial no. 60/068,285, filed on December 19, 1997.

**In the Claims:**

Please delete claims 1-12 currently of record leaving claims 13-28 pending in the divisional application. Please amend claims 13, 16-25, 27 and 28 as follows. Please calculate the claim fee after the present amendment is entered.

13. (Amended) An isolated nucleic acid molecule encoding a HA binding peptide comprising:

(a) a sequence of the formula I:



wherein

each  $X_1$  is independently selected from a hydroxy amino acid residue;

each  $X_2$  is independently selected from a sulfur containing amino acid residue;

each  $X_3$  is independently selected from a basic amino acid residue;


each  $X_4$  is independently selected from an imino or aromatic amino acid residue;

each  $X_5$  is independently selected from a dicarboxylic acid amino acid residue; and

each  $X_6$  is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:



wherein


each  $Y_1$  is independently selected from a hydroxy amino acid residue;

each  $Y_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Y_3$  is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:



wherein


each  $Z_1$  is independently selected from a hydroxy amino acid residue;

each  $Z_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Z_3$  is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

16. (Amended) A method of modulating cell locomotion comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides to a cell or animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:



wherein

each  $X_1$  is independently selected from a hydroxy amino acid residue;

each  $X_2$  is independently selected from a sulfur containing amino acid residue;

each  $X_3$  is independently selected from a basic amino acid residue;


each  $X_4$  is independently selected from an imino or aromatic amino acid residue;

each  $X_5$  is independently selected from a dicarboxylic acid amino acid residue; and

each  $X_6$  is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:



wherein


each  $Y_1$  is independently selected from a hydroxy amino acid residue;

each  $Y_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Y_3$  is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:



wherein

each  $Z_1$  is independently selected from a hydroxy amino acid residue;

each  $Z_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Z_3$  is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

17. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding peptide (HA

binding) to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence TMTRPHFHKRQLVLS.


18. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSCHH.

19. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSHH.

20. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSHHV.

21. (Amended) A method of preventing or inhibiting tissue fibrosis comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides to an animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:



wherein

each  $X_1$  is independently selected from a hydroxy amino acid residue;

each  $X_2$  is independently selected from a sulfur containing amino acid residue;

each  $X_3$  is independently selected from a basic amino acid residue;

each  $X_4$  is independently selected from an imino or aromatic amino acid residue;

each  $X_5$  is independently selected from a dicarboxylic acid amino acid residue; and

each  $X_6$  is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:

$Y_1 - Y_1 - Y_2 - Y_2 - Y_1 - Y_3 - Y_1 - Y_3 - Y_3 - Y_1 - Y_3 - Y_1 - Y_2 - Y_3 - Y_3$

wherein

each  $Y_1$  is independently selected from a hydroxy amino acid residue;

each  $Y_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Y_3$  is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:

$Z_1 - Z_1 - Z_2 - Z_2 - Z_1 - Z_3 - Z_1 - Z_3 - Z_3 - Z_1 - Z_3 - Z_1 - Z_3 - Z_3$

wherein

each  $Z_1$  is independently selected from a hydroxy amino acid residue;

each  $Z_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Z_3$  is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

22. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence TMTRPHFHKRQLVLS.

23. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSCHH.


24. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSHH.

25. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA

binding) peptide to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMRSRSHKTRSHHV.

27. (Amended) A method of treating or preventing cancer comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides to an animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:



wherein

each  $X_1$  is independently selected from a hydroxy amino acid residue;

each  $X_2$  is independently selected from a sulfur containing amino acid residue;

each  $X_3$  is independently selected from a basic amino acid residue;


each  $X_4$  is independently selected from an imino or aromatic amino acid residue;

each  $X_5$  is independently selected from a dicarboxylic acid amino acid residue; and

each  $X_6$  is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:



wherein


each  $Y_1$  is independently selected from a hydroxy amino acid residue;

each  $Y_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Y_3$  is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:



wherein


each  $Z_1$  is independently selected from a hydroxy amino acid residue;

each  $Z_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Z_3$  is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

28. (Amended) A method of preventing or reducing the metastasis of cancer cells comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides to an animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:



wherein

each  $X_1$  is independently selected from a hydroxy amino acid residue;

each  $X_2$  is independently selected from a sulfur containing amino acid residue;

each  $X_3$  is independently selected from a basic amino acid residue;


each  $X_4$  is independently selected from an imino or aromatic amino acid residue;

each  $X_5$  is independently selected from a dicarboxylic acid amino acid residue; and

each  $X_6$  is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:



wherein


each  $Y_1$  is independently selected from a hydroxy amino acid residue;

each  $Y_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Y_3$  is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:



wherein

each  $Z_1$  is independently selected from a hydroxy amino acid residue;

each  $Z_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Z_3$  is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.


**REMARKS**

By the present amendment, claims 13-28 have been amended to remove the claim dependencies on the deleted claims and to incorporate the subject matter of the deleted claims where appropriate. The amendment does not contain new matter. Please enter the amendment prior to calculating the claim fees.

Entry of the above preliminary amendment is respectfully requested.

Respectfully submitted,

**EVA TURLEY**

A handwritten signature in cursive script, appearing to read "M. Gravelle", is written over a horizontal line.

Micheline Gravelle  
Registration No. 40,261

Dated: June 18, 2001

Bereskin & Parr  
Box 401, 40 King Street West  
Toronto, Ontario  
Canada M5H 3Y2

(416) 364-7311

2001 JUN 18 10 40 AM  
MICHÈLE GRAVELLE  
REGISTRATION NO. 40,261  
BESKIN & PARR  
40 KING STREET WEST  
TORONTO, ONTARIO  
M5H 3Y2  
(416) 364-7311



**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph at page 1, lines 3 to 5 has been amended as follows:

This application is a divisional of U.S. Patent Application Serial no. 09/210,896 filed on December 16, 1998 which [This] claims the benefit under 35 USC§119(e) of United States provisional application serial no. 60/068,285, filed on December 19, 1997.

**In the Claims:**

Claims 1-12 have been cancelled.

Claims 13-28 are now pending in the divisional application.

Claims 13, 16-25, 27 and 28 have been amended as follows

13. (Amended) An isolated nucleic acid molecule encoding a HA binding peptide [according to claim 1] comprising:

(a) a sequence of the formula I:

X<sub>1</sub> - X<sub>2</sub> - X<sub>1</sub> - X<sub>3</sub> - X<sub>4</sub> - X<sub>3</sub> - X<sub>4</sub> - X<sub>3</sub> - X<sub>3</sub> - X<sub>3</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>6</sub> - X<sub>6</sub> - X<sub>1</sub>

wherein

each X<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each X<sub>2</sub> is independently selected from a sulfur containing amino acid residue;

each X<sub>3</sub> is independently selected from a basic amino acid residue;

each X<sub>4</sub> is independently selected from an imino or aromatic amino acid residue;

each X<sub>5</sub> is independently selected from a dicarboxylic acid amino acid residue; and

each X<sub>6</sub> is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:

Y<sub>1</sub> - Y<sub>1</sub> - Y<sub>2</sub> - Y<sub>2</sub> - Y<sub>1</sub> - Y<sub>3</sub> - Y<sub>1</sub> - Y<sub>3</sub> - Y<sub>3</sub> - Y<sub>1</sub> - Y<sub>3</sub> - Y<sub>1</sub> - Y<sub>2</sub> - Y<sub>3</sub> - Y<sub>3</sub>

wherein

each Y<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each Y<sub>2</sub> is independently selected from a sulfur containing amino acid residue; and

each Y<sub>3</sub> is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:

Z<sub>1</sub>-Z<sub>1</sub>-Z<sub>2</sub>-Z<sub>2</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>3</sub>

wherein

each Z<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each Z<sub>2</sub> is independently selected from a sulfur containing amino acid residue; and

each Z<sub>3</sub> is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

16. (Amended) A method of modulating cell locomotion comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides [according to claim 1] to a cell or animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:

X<sub>1</sub>-X<sub>2</sub>-X<sub>1</sub>-X<sub>3</sub>-X<sub>4</sub>-X<sub>3</sub>-X<sub>4</sub>-X<sub>3</sub>-X<sub>3</sub>-X<sub>3</sub>-X<sub>5</sub>-X<sub>6</sub>-X<sub>6</sub>-X<sub>6</sub>-X<sub>1</sub>

wherein

each X<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each X<sub>2</sub> is independently selected from a sulfur containing amino acid residue;

each X<sub>3</sub> is independently selected from a basic amino acid residue;

each X<sub>4</sub> is independently selected from an imino or aromatic amino acid residue;

each X<sub>5</sub> is independently selected from a dicarboxylic acid amino acid residue; and

each X<sub>6</sub> is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:

Y<sub>1</sub>-Y<sub>1</sub>-Y<sub>2</sub>-Y<sub>2</sub>-Y<sub>1</sub>-Y<sub>3</sub>-Y<sub>1</sub>-Y<sub>3</sub>-Y<sub>3</sub>-Y<sub>1</sub>-Y<sub>3</sub>-Y<sub>1</sub>-Y<sub>2</sub>-Y<sub>3</sub>-Y<sub>3</sub>

wherein

each Y<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each Y<sub>2</sub> is independently selected from a sulfur containing amino acid residue; and

each Y<sub>3</sub> is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:

Z<sub>1</sub>-Z<sub>1</sub>-Z<sub>2</sub>-Z<sub>2</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>3</sub>

wherein

each Z<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each Z<sub>2</sub> is independently selected from a sulfur containing amino acid residue; and

each Z<sub>3</sub> is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

17. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding peptide (HA binding) [according to claim 3] to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence TMTRPHFKRQLVLS.

18. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide [according to claim 6] to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSCHH.

19. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide [according to claim 9] to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSHH.

20. (Amended) A method of modulating cell locomotion according to claim 16 comprising administering an effective amount of hyaluronan-binding (HA binding)

peptide [according to claim 11] to a cell or animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSHHV.

21. (Amended) A method of preventing or inhibiting tissue fibrosis comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides [according to claim 1] to an animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:

$X_1 - X_2 - X_1 - X_3 - X_4 - X_3 - X_4 - X_3 - X_3 - X_3 - X_5 - X_6 - X_6 - X_1$

wherein

each  $X_1$  is independently selected from a hydroxy amino acid residue;

each  $X_2$  is independently selected from a sulfur containing amino acid residue;

each  $X_3$  is independently selected from a basic amino acid residue;

each  $X_4$  is independently selected from an imino or aromatic amino acid residue;

each  $X_5$  is independently selected from a dicarboxylic acid amino acid residue; and

each  $X_6$  is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:

$Y_1 - Y_1 - Y_2 - Y_2 - Y_1 - Y_3 - Y_1 - Y_3 - Y_3 - Y_1 - Y_3 - Y_1 - Y_2 - Y_3 - Y_3$

wherein

each  $Y_1$  is independently selected from a hydroxy amino acid residue;

each  $Y_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Y_3$  is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:

$Z_1 - Z_1 - Z_2 - Z_2 - Z_1 - Z_3 - Z_1 - Z_3 - Z_3 - Z_1 - Z_3 - Z_1 - Z_3 - Z_3$

wherein

each  $Z_1$  is independently selected from a hydroxy amino acid residue;

each  $Z_2$  is independently selected from a sulfur containing amino acid residue; and

each Z<sub>3</sub> is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

22. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide [according to claim 3] to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence TMTRPHFHKRQLVLS.

23. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide [according to claim 6] to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSCHH.

24. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide [according to claim 9] to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSHH.

25. (Amended) A method of preventing or inhibiting tissue fibrosis according to claim 21 comprising administering an effective amount of hyaluronan-binding (HA binding) peptide [according to claim 11] to an animal in need thereof, wherein said HA binding peptide comprises the amino acid sequence STMMSRSHKTRSHHV.

27. (Amended) A method of treating or preventing cancer comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides [according to claim 1] to an animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:

X<sub>1</sub> - X<sub>2</sub> - X<sub>1</sub> - X<sub>3</sub> - X<sub>4</sub> - X<sub>3</sub> - X<sub>4</sub> - X<sub>3</sub> - X<sub>3</sub> - X<sub>3</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>6</sub> - X<sub>6</sub> - X<sub>1</sub>

wherein

each X<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each X<sub>2</sub> is independently selected from a sulfur containing amino acid residue;

each X<sub>3</sub> is independently selected from a basic amino acid residue;

each X<sub>4</sub> is independently selected from an imino or aromatic amino acid residue;

each X<sub>5</sub> is independently selected from a dicarboxylic acid amino acid residue; and

each X<sub>6</sub> is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:

Y<sub>1</sub>-Y<sub>1</sub>-Y<sub>2</sub>-Y<sub>2</sub>-Y<sub>1</sub>-Y<sub>3</sub>-Y<sub>1</sub>-Y<sub>3</sub>-Y<sub>3</sub>-Y<sub>1</sub>-Y<sub>3</sub>-Y<sub>1</sub>-Y<sub>2</sub>-Y<sub>3</sub>-Y<sub>3</sub>

wherein

each Y<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each Y<sub>2</sub> is independently selected from a sulfur containing amino acid residue; and

each Y<sub>3</sub> is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:

Z<sub>1</sub>-Z<sub>1</sub>-Z<sub>2</sub>-Z<sub>2</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>1</sub>-Z<sub>3</sub>-Z<sub>3</sub>

wherein

each Z<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each Z<sub>2</sub> is independently selected from a sulfur containing amino acid residue; and

each Z<sub>3</sub> is independently selected from a basic amino acid residue, and fragments, analogs or derivatives of the peptide which bind HA.

28. (Amended) A method of preventing or reducing the metastasis of cancer cells comprising administering an effective amount of one or more hyaluronan-binding (HA binding) peptides [according to claim 1] to an animal in need thereof, wherein said HA binding peptide comprises:

(a) a sequence of the formula I:

X<sub>1</sub>-X<sub>2</sub>-X<sub>1</sub>-X<sub>3</sub>-X<sub>4</sub>-X<sub>3</sub>-X<sub>4</sub>-X<sub>3</sub>-X<sub>3</sub>-X<sub>3</sub>-X<sub>5</sub>-X<sub>6</sub>-X<sub>6</sub>-X<sub>1</sub>

wherein

each X<sub>1</sub> is independently selected from a hydroxy amino acid residue;

each  $X_2$  is independently selected from a sulfur containing amino acid residue;

each  $X_3$  is independently selected from a basic amino acid residue;

each  $X_4$  is independently selected from an imino or aromatic amino acid residue;

each  $X_5$  is independently selected from a dicarboxylic acid amino acid residue; and

each  $X_6$  is independently selected from an aliphatic amino acid residue,

and fragments, analogs or derivatives of the peptide which can bind HA;

(b) a sequence of the formula II:

$Y_1 - Y_1 - Y_2 - Y_2 - Y_1 - Y_3 - Y_1 - Y_3 - Y_3 - Y_1 - Y_3 - Y_1 - Y_2 - Y_3 - Y_3$

wherein

each  $Y_1$  is independently selected from a hydroxy amino acid residue;

each  $Y_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Y_3$  is independently selected from a basic amino acid residue,

and fragments, analogs or derivatives of the peptide which bind HA; or

(c) a sequence of the formula III:

$Z_1 - Z_1 - Z_2 - Z_2 - Z_1 - Z_3 - Z_1 - Z_3 - Z_3 - Z_1 - Z_3 - Z_1 - Z_3 - Z_3$

wherein

each  $Z_1$  is independently selected from a hydroxy amino acid residue;

each  $Z_2$  is independently selected from a sulfur containing amino acid residue; and

each  $Z_3$  is independently selected from a basic amino acid residue, and fragments,

analogs or derivatives of the peptide which bind HA.